Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Jun 3, 2020
Industry call for COVID-19 convalescent plasma collections
The treatment of COVID-19 patients, especially in severe conditions, presents a challenge to medical professionals. Plasma from recovered COVID-19 patients is a potential and promising therapeutic option, and efforts are underway at different levels to encourage convalescent plasma donations [1, 2].
All
Publication
https://onlinelibrary.wiley.com/doi/full/10.1111/voxs.12571
Jun 3, 2020
Industry call for COVID-19 convalescent plasma collections
The treatment of COVID-19 patients, especially in severe conditions, presents a challenge to medical professionals. Plasma from recovered COVID-19 patients is a potential and promising therapeutic option, and efforts are underway at different levels to encourage convalescent plasma donations [1, 2].
All
Publication
https://onlinelibrary.wiley.com/doi/full/10.1111/voxs.12571
Jun 1, 2020
The Source Summer 2020
Magazine of the plasma protein therapeutics industry - Summer 2020
All
The Source Magazine
https://drive.google.com/file/d/1nLFNgHSD4LcL0DLgbtbKufxP4qs0VUhW/view?usp=sharing
Jun 1, 2020
The Source Summer 2020
Magazine of the plasma protein therapeutics industry - Summer 2020
All
The Source Magazine
https://drive.google.com/file/d/1nLFNgHSD4LcL0DLgbtbKufxP4qs0VUhW/view?usp=sharing
May 1, 2020
Physicians in European Plasma Collection Centers
Many European countries have regulatory systems, which require the presence of a physician at all times in plasma collection centers.
All
Advocacy
https://plasmaprotein.sharepoint.com/:b:/s/EU/EUlhH2KT7FtCh5puxKTq7oQB2LUBty3vutdZqorv3FK8_w?e=lQ7y56
May 1, 2020
Physicians in European Plasma Collection Centers
Many European countries have regulatory systems, which require the presence of a physician at all times in plasma collection centers.
All
Advocacy
https://plasmaprotein.sharepoint.com/:b:/s/EU/EUlhH2KT7FtCh5puxKTq7oQB2LUBty3vutdZqorv3FK8_w?e=lQ7y56
Apr 3, 2020
New Coronavirus (SARS-CoV-2) and the Safety Margins of Plasma Protein Therapies
PPTA considers that the SARS-CoV-2 outbreak is not a concern for the safety of plasma protein therapies manufactured by PPTA member companies. The assessment is shared by notable international and national public health bodies, including the WHO, the ECDC, and others.
All
PPTA statements
Apr 3, 2020
New Coronavirus (SARS-CoV-2) and the Safety Margins of Plasma Protein Therapies
PPTA considers that the SARS-CoV-2 outbreak is not a concern for the safety of plasma protein therapies manufactured by PPTA member companies. The assessment is shared by notable international and national public health bodies, including the WHO, the ECDC, and others.
All
PPTA statements
No results found